Third quarter GAAP net loss attributable to Solazyme, Inc. common stockholders was $30.7 million, which compares with net loss of $22.5 million in the prior year period. On a non-GAAP basis, the net loss was $22.3 million for the third quarter of 2013, compared with net loss of $19.4 million in the prior year quarter. A reconciliation of GAAP to non-GAAP results is included below.“We continue to closely manage our expenses and are well-capitalized to broadly commercialize our technology in 2014,” said Tyler Painter, CFO of Solazyme. Recent Business Highlights
- Enters Into Supply Agreement with Unilever: In September, Solazyme and Unilever finalized their first commercial supply agreement for a Solazyme Tailored TM algal oil which includes an initial supply of at least 10,000 MT. Supply is planned to begin in early 2014.
- Enters Into Supply Agreement with Goulston Technologies: In October, Solazyme announced its entry into the textile lubricants market through a commercial supply agreement with Goulston Technologies, Inc. This agreement enables Goulston to introduce Solazyme’s algal oils into the estimated $1B textile lubricants market and the companies plan to further broaden the portfolio of Solazyme Tailored TM algal oil offerings for this market.
- Extension and Renewal of JDA agreements with Unilever and Bunge: Solazyme further deepened the relationship with the consumer packaged goods giant, Unilever, into 2014. Under the extended agreement, the companies plan to accelerate the commercialization of a second novel Tailored™ algal oil. In addition, Solazyme and Bunge extended and expanded their JDA to enable the Solazyme Bunge Renewable Oils JV to have access to a broader portfolio of oils.
- Producing Whole Algal Food Ingredients at Peoria: Solazyme has begun production of Whole Algal food ingredients at Peoria and is actively delivering samples in response to over 160 requests from food ingredients companies and other potential customers.
- Solazyme Health Sciences launches a new brand: This week, Solazyme Health Sciences launched EverDeep™, a new line of patented anti-aging skincare products that is distributed through direct response infomercials and the internet and which includes a new proprietary microalgae-based ingredient from Solazyme. This represents Solazyme’s second consumer-focused skin-care brand and a significant expansion of our Health Sciences business.
Solazyme®, the Solazyme logo and other trademarks or service names are trademarks of Solazyme, Inc.Non-GAAP Financial Measures This press release includes the following financial measure defined as a “non-GAAP financial measure” by the Securities and Exchange Commission: non-GAAP net loss. This measure may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with generally accepted accounting principles. For a reconciliation of this non-GAAP financial measure to the nearest comparable GAAP measure, see “Reconciliation of GAAP to Non-GAAP Basic Net Loss Per Share” included in the tables to this press release. This non-GAAP measure is provided to enhance investors’ overall understanding of Solazyme’s current financial performance and Solazyme’s prospects for the future. Specifically, Solazyme believes the non-GAAP measure provides useful information to both management and investors by excluding certain expenses that may not be indicative of its core operating results and business outlook. For its internal budgeting process, Solazyme’s management uses financial measures that do not include stock-based compensation expense or special expenses such as non-cash gains or losses due to warrant and/or derivative revaluations, amortization of debt discounts and issuance costs and dissolution of Joint Ventures. In addition to the corresponding GAAP measures, Solazyme’s management also uses the foregoing non-GAAP measure in reviewing the financial results of Solazyme. Solazyme excludes stock-based compensation expenses and special non-cash charges from its non-GAAP measures primarily because they are non-cash expenses that management does not believe are reflective of ongoing operating results. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Solazyme, including statements that involve risks and uncertainties concerning: its commercialization plans and commercialization timetable for products; market opportunities; application development; agreement on definitive supply terms for products, including selling prices for products; expansion into a broad collaboration and entry into definitive agreements; the attributes of the collaboration; the timetable for completion and capacity of facilities; the timetable for bringing facilities online and manufacturing products; the ability to bring manufacturing facilities online with partners; the ability to have access and/or continue to have access to manufacturing facilities constructed and/or owned by partners; development of additional products; meeting commercialization and technology targets and other objectives; its capital structure; and Solazyme’s ability to maintain its relationships with its partners and customers. When used in this press release, the words “will”, “expects”, “intends” and other similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Solazyme, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this press release due to a number of risks and uncertainties. Potential risks and uncertainties include, among others: Solazyme’s limited operating history; its limited history in commercializing products; implementation risk in deploying new technologies; its limited experience in constructing and operating commercial manufacturing facilities; market acceptance of its products; its ability to sell its products at a profit; delays related to construction, start-up, ramp-up, or funding of production facilities; its access to adequate supply of feedstock on favorable terms; its ability to manage operational costs at production facilities; its ability to enter into and maintain strategic collaborations, including the funding thereof; its ability to obtain requisite regulatory approvals; and its access, on favorable terms, to any required financing. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Solazyme.
In addition, please refer to the documents that Solazyme, Inc. files with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2013, for a discussion of these and other risks. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. Solazyme is not under any duty to update any of the information in this press release.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|In thousands, except per share amounts|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|Research and development programs||$||5,824||$||4,810||$||14,764||$||23,838|
|Costs and operating expenses (1)|
|Cost of product revenue||1,450||1,331||4,400||3,907|
|Research and development||17,556||16,534||46,191||50,276|
|Sales, general and administrative||15,708||13,849||46,010||41,628|
|Total costs and operating expenses||34,714||31,714||96,601||95,811|
|Loss from operations||(24,093||)||(23,131||)||(68,125||)||(60,127||)|
|Other income (expense) (2)|
|Interest and other income (expense), net||(1,614||)||626||(4,576||)||1,262|
|Loss from equity method investment||(2,360||)||(683||)||(5,541||)||(1,193||)|
|Gain (loss) from change in fair value of warrant liability||200||685||(425||)||1,536|
|Loss from change in fair value of derivative liability||(2,836||)||-||(4,386||)||-|
|Total other income (expense)||(6,610||)||628||(14,928||)||1,605|
|Net loss per share, basic and diluted||$||(0.47||)||$||(0.37||)||$||(1.32||)||$||(0.97||)|
|Weighted average number of common shares used in loss per share computation, basic and diluted||64,812||60,678||62,783||60,387|
|RECONCILIATION OF GAAP TO NON-GAAP BASIC NET LOSS PER SHARE|
|In thousands, except per share amounts|
|Three Months Ended September 30,||Nine Months Ended September 30,|
|(Gain) loss from change in fair value of warrant liability||(200||)||(685||)||425||(1,536||)|
|Loss from change in fair value of derivative liability||2,836||-||4,386||-|
|(1) Operating expenses include stock-based compensation expense as follows:|
|Research and development||1,544||1,001||4,111||2,939|
|Sales, general and administrative||3,687||2,742||10,341||8,619|
|Total stock-based compensation expense||5,231||3,743||14,452||11,558|
|(2) Other income (expense) includes costs as follows:|
|Amortization of debt discount and issuance costs||503||-||1,248||-|
|Dissolution of the Solazyme Roquette JV||59||-||1,406||-|
|Net loss (non-GAAP)||$||(22,274||)||$||(19,445||)||$||(61,136||)||$||(48,500||)|
|Basic and diluted loss per share (GAAP)||$||(0.47||)||$||(0.37||)||$||(1.32||)||$||(0.97||)|
|(Gain) loss from change in fair value of warrant liability||-||(0.01||)||0.01||(0.02||)|
|Loss from change in fair value of derivative liability||0.04||-||0.07||-|
|Stock-based compensation expense||0.08||0.06||0.23||0.19|
|Amortization of debt discount and issuance costs||0.01||-||0.02||-|
|Dissolution of the Solazyme Roquette JV||-||-||0.02||-|
|Net loss per share (non-GAAP)||$||(0.34||)||$||(0.32||)||$||(0.97||)||$||(0.80||)|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|September 30,||December 31,|
|Cash, cash equivalents and marketable securities||$||194,355||$||149,005|
|Other current assets||25,554||16,274|
|Total current assets||219,909||165,279|
|Property, plant and equipment - net||35,682||32,225|
|Liabilities and stockholders' equity|
|Current portion of long-term debt||$||63||$||7,331|
|Other current liabilities||20,331||17,607|
|Total current liabilities||20,394||24,938|
|Total stockholders' equity||165,276||183,311|
|Total liabilities and stockholders' equity||$||278,800||$||217,024|